Clinical Trial: A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758634) titled 'A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension' on Aug. 06.

Brief Summary: A Study of CTX340 in Participants with Uncontrolled Hypertension.

Study Start Date: Aug. 08

Study Type: INTERVENTIONAL

Condition: Hypertension

Intervention: DRUG: CTX340

CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.

DRUG: Placebo

One of the arms in Phase 2 will be placebo.

Recruitment Status: RECRUITING

Sponsor: CRISPR Th...